Evidence map›Paper›PMID 29636886›Full record

ArticleAmerican journal of translational research2018

COX-2 contributes to LPS-induced Stat3 activation and IL-6 production in microglial cells.

Jie Zhu, Shuzhen Li, Yue Zhang, Guixia Ding, Chunhua Zhu, Songming Huang, Aihua Zhang, Zhanjun Jia, Mei Li

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Neuroprotective Effect ofCurrent pharmaceutical biotechnology · 2024
    Article
  6. The Regulatory Roles ofInternational journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. AXL Inhibits Proinflammatory Factors to Relieve Rheumatoid Arthritis Pain by Regulating the TLR4/NF-Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jie ZhuNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Shuzhen LiNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Yue ZhangNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Guixia DingNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Chunhua ZhuNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Songming HuangNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Aihua ZhangNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Zhanjun JiaNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Mei LiNanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical UniversityNanjing 210008, P. R. China.
Nanjing Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many stimuli including lipopolysaccharide (LPS) could activate microglial cells to subsequently cause inflammatory nerve injury. However, the mechanism of LPS-induced neuroinflammation in microglial cells is still elusive. Thus, the present study was undertaken to examine the role of COX-2 in mediating the activation of Stat3 and the production of IL-6 in BV2 cells challenged with LPS. After 24 h treatment, LPS dose-dependently enhanced COX-2 expression at both mRNA and protein levels. Meanwhile, IL-6 with other inflammatory cytokines including IL-1β, TNF-α, and MCP-1 were similarly enhanced by LPS. Then a specific COX-2 inhibitor (NS-398) was administered to BV2 before LPS treatment. Significantly, COX-2 inhibition suppressed the upregulation of IL-6 at both mRNA and protein levels in line with the trend blockade on IL-1β, TNF-α, and MCP-1. Stat3 drives proinflammatory signaling pathways and contributes to IL-6 production via a transcriptional mechanism in many diseases. Here we found that inhibition of COX-2 entirely blocked LPS-induced Stat3 phosphorylation, which might contribute to the blockade of IL-6 production to some extent. Meanwhile, COX-2 siRNA approach largely reproduced the phenotypes shown by specific COX-2 inhibitor in LPS-treated BV2 cells. Together, these findings suggested that COX-2 might contribute to LPS-induced IL-6 production possibly through activating Stat3 signaling pathway in microglial cells.

Indexed as

COX-2IL-6LPSMicroglial cellsStat3

Identifiers

PMID29636886
PMCPMC5883137
OpenAlexW2916836294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.